老年胶质母细胞瘤患者的管理:文献综述
本文综述老年新诊断胶质母细胞瘤患者在手术、放疗、化疗及联合治疗方面的研究证据。65–70岁功能状态极佳者可考虑手术联合标准放疗及替莫唑胺同步和辅助化疗;70岁以上功能状态良好者可接受上述方案但采用较短疗程放疗;功能状态较差且MGMT启动子甲基化者可考虑替莫唑胺化疗;不能耐受化疗者可选择大分割放疗。与年轻成人不同,个体化方案似乎是关键。
要点
- 65–70岁功能状态极佳的老年患者可考虑手术联合标准放疗及替莫唑胺同步和辅助化疗。
- 70岁以上功能状态良好者可接受上述方案,但放疗采用较短疗程而非标准疗程。
- 功能状态较差且MGMT启动子甲基化的老年患者可考虑替莫唑胺化疗;不能耐受化疗者大分割放疗是选择之一。
核心结论
- 与年轻成人患者不同,仔细的个体化方案似乎是决定该组患者最佳治疗选择的关键要素。
研究设计与样本
- 本文为文献综述,汇总手术、放疗、化疗及其联合治疗在老年新诊断胶质母细胞瘤患者中的研究结果。
主要发现
- 高级别胶质瘤是最常见的原发性侵袭性脑肿瘤,预后极差,中位生存期不足2年。
- 新诊断胶质母细胞瘤的标准治疗方案包括手术、放疗、替莫唑胺化疗及后续辅助替莫唑胺。
- 高级别胶质瘤分子分型的近期进展进一步加深了对该疾病的理解。
- 新诊断成人胶质母细胞瘤的管理已标准化,但新诊断老年胶质母细胞瘤患者的最佳治疗方式仍存大量争议。
关键数值与推荐
- 65–70岁功能状态极佳的老年患者可考虑接受手术、标准放疗联合替莫唑胺同步及辅助化疗的标准治疗。
- 70岁以上功能状态良好的老年患者可接受上述方案,但接受较短疗程放疗而非标准放疗。
- 功能状态较差且MGMT启动子甲基化的老年胶质母细胞瘤患者可考虑替莫唑胺化疗。
- 不能耐受化疗的老年患者,大分割放疗是一种选择。
临床怎么用
- 老年胶质母细胞瘤患者的功能状态和年龄是考虑治疗方案的因素,65–70岁功能状态极佳者可考虑标准治疗。
- 70岁以上功能状态良好者可考虑标准方案但采用较短疗程放疗。
- 功能状态较差且MGMT启动子甲基化者可考虑替莫唑胺化疗,不能耐受化疗者可选择大分割放疗。
- 作者认为仔细的个体化方案似乎是决定该组患者最佳治疗选择的关键要素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High grade gliomas are the most common primary aggressive brain tumours with a very poor prognosis and a median survival of less than 2 years. The standard management protocol of newly diagnosed glioblastoma patients involves surgery followed by radiotherapy, chemotherapy in the form of temozolomide and further adjuvant temozolomide. The recent advances in molecular profiling of high-grade gliomas have further enhanced our understanding of the disease. Although the management of glioblastoma is standardised in newly diagnosed adult patients there is a lot of debate regarding the best treatment approach for the newly diagnosed elderly glioblastoma patients. In this review article we attempt to summarise the findings regarding surgery, radiotherapy, chemotherapy, and their combination in order to offer the best possible management modality for this group of patients. Elderly patients 65-70 with an excellent functional level could be considered as candidates for the standards treatment consisting of surgery, standard radiotherapy with concomitant and adjuvant temozolomide. Similarly, elderly patients above 70 with good functional status could receive the above with the exception of receiving a shorter course of radiotherapy instead of standard. In elderly GBM patients with poorer functional status and MGMT promoter methylation temozolomide chemotherapy can be considered. For elderly patients who cannot tolerate chemotherapy, hypofractionated radiotherapy is an option. In contrast to the younger adult patients, it seems that a careful individualised approach is a key element in deciding the best treatment options for this group of patients.
引用
- Mazarakis NK, Robinson SD, Sinha P, et al. Management of glioblastoma in elderly patients: A review of the literature. Clin Transl Radiat Oncol. 2024. PMID: 38500668. doi:10.1016/j.ctro.2024.100761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。